Evidence map›Paper›PMID 24528611›Full record

ArticleCritical care (London, England)2014

Skeletal muscle mass and mortality - but what about functional outcome?

Zudin A Puthucheary, Nicholas Hart

2 registry-linked trialsOpen access · goldAbstract readComment
In one paragraph

Article in Critical care (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02358512 phase2completednot on this mapstarted 2015, after this paper: background citation

A Phase 2 Pilot Physiological Randomised Clinical Trial to Investigate the Effect of Intermittent Versus Continuous Enteral Nutrition on Muscle Wasting in Critical Illness

TypeinterventionalSponsorGuy's and St Thomas' NHS Foundation TrustRan2015 to 2018Enrolled127ConditionsIntensive Care (ICU) MyopathyArmsEnteral feeding
NCT02773771 phase2 / phase3withdrawnnot on this mapstarted 2017, after this paper: background citation

Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit (STROMA-ICU)

TypeinterventionalSponsorMassachusetts General HospitalRan2017 to 2019Enrolled0ConditionsMuscle AtrophyArmsbeta-hydroxy-beta-methylbutyrate, Placebo, Vital HP®
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Deaccelerated Myogenesis and Autophagy in Genetically Induced Pulmonary Emphysema.American journal of respiratory cell and molecular biology · 2022
    Article
  9. Review
  10. Article
  11. Observational
  12. AMP-Activated Protein Kinase (AMPK) at the Crossroads Between COInternational journal of molecular sciences · 2020
    Review
  13. Article
  14. Article
  15. Hand grip strength and chronic obstructive pulmonary disease in Korea: an analysis in KNHANES VI.International journal of chronic obstructive pulmonary disease · 2017
    Article
  16. Article
  17. Article
  18. Primary care - The unrecognized member of the intensive care team.Journal of the Intensive Care Society · 2015
    Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Zudin A Puthucheary
Nicholas Hart
King's College London · GBUniversity College London · GB

Funding

Department of Health DRF-2010-03-114
6 · The paper itself

Abstract

We have known for over a decade that critical illness survivors suffer from significant functional disability after hospital discharge. Muscle wasting is a major contributor to this disability, occurring early and rapidly during critical illness, with the subsequent weakness associated with delayed weaning and prolonged hospital stay. The scale of this long-term public health issue is concerning for two important reasons: increasing numbers of patients survive critical illness, and this is compounded by the lack of interventions to reduce skeletal muscle wasting to combat the functional disability. In the current issue of Critical Care, Weijs and colleagues demonstrate an indirect relationship between skeletal muscle mass on admission to the ICU and mortality. Observational data were obtained from 240 critically ill patients, all of whom received abdominal computer tomography scans for clinical reasons. Skeletal muscle volume was calculated for all visible skeletal muscle at the level of the third lumbar vertebra. In both continuous and categorical regression analysis, lower muscle volume on admission was associated with higher mortality, independent of Acute Physiology and Chronic Health Evaluation II score and gender. Interestingly, no association was observed between mortality and body mass index. These data also demonstrate that more than twice as many critical illness survivors with a low muscle mass on admission, compared to those with preserved muscle mass, were discharged to a nursing home. While this approach is novel and the results support the current clinical view in this area, one must regard these data with caution. Clinically relevant details, such as prior functional status, are not available. Despite these caveats, this study has two main messages. Firstly, muscle mass on admission to the ICU is a predictor of mortality and this physiological biomarker should therefore strongly be considered as an outcome measure in interventional studies. Secondly, low admission muscle mass is associated with increased disability and, in the case of this study, associated with an increased frequency of discharge to nursing homes. Further investigation is required to demonstrate the relationship between muscle mass, functional ability and discharge location.

Indexed as

Critical IllnessFemaleHumansMaleMuscle, SkeletalRadiographyRespiration, Artificial

Identifiers

PMID24528611
PMCPMC4057190
OpenAlexW2124668716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.